TABLE 1.
Baseline Characteristics Before Starting 177Lu-PSMA
| Characteristic | Data |
|---|---|
| Total patients | 49 (100) |
| Age (y) | 72 (57–83) |
| Eastern Cooperative Oncology Group performance status (baseline) | |
| 0 | 0 (0) |
| 1 | 36 (73) |
| 2 | 13 (27) |
| 3–4 | 0 (0) |
| Prostate-specific antigen (ng/mL) | 287.0 (20–12,229) |
| Alkaline phosphatase (U/L) | 142.5 (48–730) |
| Visceral metastatic disease | 15 (31) |
| ≥4 life-prolonging therapies* | 30 (61) |
| Novel antiandrogen therapies | |
| Abiraterone | 39 (80) |
| Enzalutamide | 33 (67) |
| Abiraterone and enzalutamide | 33 (67) |
| Number of any taxane-based chemotherapy lines† | |
| 0 | 4 (8) |
| 1 | 35 (71) |
| ≥2 | 10 (20) |
| Docetaxel | 45 (92) |
| Number of docetaxel cycles‡ | |
| 1–4 | 10 (20) |
| ≥5 | 26 (53) |
| Cabazitaxel | 9 (18) |
| Number of cabazitaxel cycles‡ | |
| 1–4 cycles | 0 (0) |
| ≥5 cycles | 5 (10) |
| Taxane-based chemotherapy between 223Ra and 177Lu-PSMA§ | 25 (51) |
*
Docetaxel, cabazitaxel, abiraterone, enzalutamide, and 223Ra.
†
Chemotherapies with same start date ± 15 d are counted as 1 line.
‡
Not available for some patients.
§
After last 223Ra dose and 60 d before 177Lu-PSMA.
Qualitative data are number and percentage; continuous data are median and range.